Effect and safety of semaglutide 2.4 mg once-weekly as adjunct to intensive behavioural therapy in subjects with overweight or obesity Save

Date Added
June 26th, 2018
PRO Number
Pro00078980
Researcher
Patrick O'neil

Silhouette
Keywords
Drug Studies, Obesity, Weight Control
Summary

The study seeks to determine how well semaglutide, the study medication, works in people suffering from overweight or obesity over a period of 68 weeks along with a 7-week follow-up period. Participants will be randomly assigned to receive semaglutide or an inactive placebo. All participants will receive intensive lifestyle change counseling including a low-calorie diet. Participants will inject themselves once-weekly with study medication. The primary measure of the study will be weight change.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity Save

Date Added
May 22nd, 2018
PRO Number
Pro00077418
Researcher
Patrick O'neil

Silhouette
Keywords
Drug Studies, Obesity, Weight Control
Summary

The study seeks to determine how well semaglutide, the study medication, works in people suffering from overweight or obesity over a period of 68 weeks along with a 7-week follow-up period. Participants will be randomly assigned to receive semaglutide or an inactive placebo. All participants will receive diet and physical activity counseling. Participants will inject themselves once-weekly with study medication. The primary measure of the study will be weight change.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma Save

Date Added
February 28th, 2017
PRO Number
Pro00062918
Researcher
David Koch

Silhouette
Keywords
Cancer, Cancer/Gastrointestinal, Cancer/Other, Digestive System, Genetics, Liver, Obesity, Weight Control
Summary

TARGET-HCC is a 5-year, longitudinal, observational study of the natural history and management of patients with HCC. The study will address important clinical questions that remain unanswered in the management of HCC with a unique research registry of participants with HCC from academic and community real-world practices. TARGET-HCC is disease focused, not drug specific, which allows for continuous acquisition of real-world evidence regarding the natural history, management, and outcomes of treatment with current therapies and new treatments that may be utilized in usual clinical practice.

Institution
MUSC
Recruitment Contact
Francis Beylotte
843-876-4273
beylott@musc.edu

Change_preferences

-- OR --

Create_login